We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+9.41%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$1.08B
(+126%)
Cap. Flow
+$347M
Cap. Flow
% of AUM
17.97%
Top 10 Holdings %
Top 10 Hldgs %
58.78%
Holding
104
New
42
Increased
25
Reduced
17
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARK Genomic Revolution ETF
ARKG
|
+$80M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$31.3M |
| 3 |
OCDX
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
|
+$24.2M |
| 4 |
Community Health Systems
CYH
|
+$23.5M |
| 5 |
McKesson
MCK
|
+$22.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$23.6M |
| 2 |
The Ensign Group
ENSG
|
+$15.4M |
| 3 |
CTLT
CATALENT, INC.
CTLT
|
+$13M |
| 4 |
HSKA
Heska Corp
HSKA
|
+$11.5M |
| 5 |
RAD
Rite Aid Corporation
RAD
|
+$10.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.91% |
| 2 | Miscellaneous | 40.99% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
PUT
ARK Genomic Revolution ETF
ARKG
$1.88B
| $5.05M | 0.26% |
+56,900
| New | +$5.64M |
|
52
Seres Therapeutics
MCRB
$51.3M
| $4.43M | 0.23% |
10,764
-5,938
| -36% | -$2.73M |
|
|
LMNX
53
DELISTED
Luminex Corp
LMNX
| $4.33M | 0.22% |
+135,471
| New | +$4.02M |
|
54
Immunovant
IMVT
$8.51B
| $3.69M | 0.19% |
+230,183
| New | +$6.07M |
|
|
FPRX
55
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $3.51M | 0.18% |
93,280
-115,875
| -55% | -$2.89M |
|
56
CALL
Centene
CNC
$32B
| $3.2M | 0.17% |
+50,000
| New | +$3.1M |
|
|
AMRN
57
CALL
Amarin Corp
AMRN
$295M
| $2.74M | 0.14% |
22,040
-42,230
| -66% | -$5.68M |
|
|
58
The Ensign Group
ENSG
$10.1B
| $2.71M | 0.14% |
28,883
-179,587
| -86% | -$15.4M |
|
|
SRDX
59
DELISTED
Surmodics
SRDX
| $2.69M | 0.14% |
47,906
+6,607
| +16% | +$330K |
|
60
Humacyte
HUMA
$181M
| $2.59M | 0.13% |
+239,026
| New | +$2.61M |
|
61
Lexicon Pharmaceuticals
LXRX
$1.02B
| $2.41M | 0.12% |
+410,593
| New | +$2.84M |
|
62
Agilent Technologies
A
$43.4B
| $1.94M | 0.1% |
15,261
+10,284
| +207% | +$1.27M |
|
63
Intuitive Surgical
ISRG
$132B
| $1.91M | 0.1% |
+7,749
| New | +$1.95M |
|
|
HSKA
64
DELISTED
Heska Corp
HSKA
| $1.86M | 0.1% |
11,040
-65,126
| -86% | -$11.5M |
|
65
PUT
Korro Bio
KRRO
$190M
| $1.84M | 0.1% |
+3,872
| New | +$7.52M |
|
66
Exagen
XGN
$179M
| $1.83M | 0.09% |
104,437
+22,834
| +28% | +$407K |
|
67
CALL
Novavax
NVAX
$1.53B
| $1.81M | 0.09% |
+10,000
| New | +$1.99M |
|
68
Prothena Corp
PRTA
$479M
| $1.72M | 0.09% |
68,575
-134,753
| -66% | -$2.54M |
|
69
Keros Therapeutics
KROS
$219M
| $1.7M | 0.09% |
+27,631
| New | +$1.75M |
|
|
XENT
70
DELISTED
Intersect ENT, Inc
XENT
| $1.57M | 0.08% |
+75,389
| New | +$1.74M |
|
|
TLGT
71
DELISTED
Teligent, Inc
TLGT
| $1.56M | 0.08% |
+2,500,260
| New | +$2.35M |
|
|
CFMS
72
DELISTED
Conformis, Inc. Common Stock
CFMS
| $1.53M | 0.08% |
+61,679
| New | +$1.66M |
|
73
Liquidia Corp
LQDA
$6.06B
| $1.35M | 0.07% |
+500,010
| New | +$1.48M |
|
74
IQVIA
IQV
$43.1B
| $1.14M | 0.06% |
5,921
+1,836
| +45% | +$345K |
|
75
Chewy
CHWY
$9.52B
| $1.11M | 0.06% |
+13,100
| New | +$1.27M |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Eversept Partners held 104 positions worth $1.93B, up 126% from $852M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Eversept Partners deployed $347M of net new capital in Q1 2021, opening 42 new positions and adding to 25 existing holdings. Its largest new stake was ARK Genomic Revolution ETF: 806,932 shares worth $71.6M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
On the sell side, the largest reduction was The Ensign Group, an estimated $15.4M trimmed.
- Eversept Partners's largest Q1 2021 buy was ARK Genomic Revolution ETF: 806,932 shares worth $71.6M.
- Eversept Partners added most to Community Health Systems in Q1 2021, an estimated $23.5M increase.
- Eversept Partners's biggest Q1 2021 reduction was The Ensign Group, cutting an estimated $15.4M.
- Eversept Partners fully exited Sarepta Therapeutics in Q1 2021, selling an estimated $23.6M.
- Eversept Partners's ten largest holdings make up 59% of its $1.93B portfolio in Q1 2021.
- Eversept Partners opened 42 new positions and closed 19 in Q1 2021.
- Eversept Partners's portfolio value rose 126% quarter-over-quarter to $1.93B.
Based on Eversept Partners's 13F filing for Q1 2021, filed 13 May 2021.